National Health Act 1953 - Arrangements made under subparagraph 100(1)(b)(i) - Highly Specialised Drugs Program (No. PB 42 of 2006)
DefinitionsDefinitions
Start here
Get a plain-English read of Definitions
Turn the raw legal text into a practical explanation grounded in National Health Act 1953 - Arrangements made under subparagraph 100(1)(b)(i) - Highly Specialised Drugs Program (No. PB 42 of 2006).
Definitions
- In these Arrangements:
(a) unless the contrary intention appears, a word or phrase will be taken to have the same meaning as in the Act, the Regulations or a declaration, determination or other instrument made under Part VII of the Act or under the Regulations;
(b) “Act” means the National Health Act 1953;
(c) “Medicare Australia CEO” means the Chief Executive Officer of Medicare Australia;
(d) “details of the prescription”, for the purpose of subparagraph 11(b), means:
(i) all matters included in the prescription completed by the medical practitioner in accordance with subparagraph 11(a); and
(ii) the proposed duration of treatment for which authority is sought by the medical practitioner; and
(iii) the provider number of the hospital with which the medical practitioner is affiliated;
(e) “highly specialised drug” means a special pharmaceutical product in relation to which, by virtue of paragraphs 4, 7 and 9, these Arrangements apply;
(f) “medical practitioner” means a medical practitioner, within the meaning of the Health Insurance Act 1973, who is affiliated with the hospital in or at which the patient is receiving treatment and is:
(i) a staff hospital specialist; or
(ii) a visiting or consulting specialist of the hospital; or
(iii) providing maintenance therapy in a situation where it is impractical to obtain a prescription from, and with the agreement of, a medical practitioner referred to in subsubparagraph (i) or (ii); or
(iv) accredited, in the State or Territory in which the medical practitioner practises, to prescribe medication for the treatment of HIV or AIDS; or
(v) the subject of a specific arrangement between the Commonwealth and the relevant State or Territory Government;
(g) “medication for the treatment of HIV or AIDS” means any of the following highly specialised drugs:
abacavir sulfate
abacavir sulfate with lamivudine
abacavir sulfate with lamivudine and zidovudine
amprenavir
atazanavir sulfate
azithromycin dihydrate
cidofovir
clarithromycin
delavirdine mesylate
didanosine
doxorubicin hydrochloride, pegylated liposomal
efavirenz
emtricitabine
enfuvirtide
fosamprenavir calcium
foscarnet sodium
ganciclovir
ganciclovir sodium
indinavir sulfate